Acute liver impairment in a young, healthy athlete : hypoxic hepatitis and rhabdomyolysis following heat stroke by Azzopardi, Neville et al.
 Case Rep Gastroenterol 2012;6:563–568 
DOI: 10.1159/000338838 
Published online: 
August 28, 2012 
© 2012 S. Karger AG, Basel 
ISSN 1662–0631 
www.karger.com/crg 
This is an Open Access article licensed under the terms of the Creative Commons 
Attribution-NonCommercial-NoDerivs 3.0 License (www.karger.com/OA-license), applicable 
to the online version of the article only. Distribution for non-commercial purposes only. 
 
 
           Dr. Neville Azzopardi, 
MD, MRCP (UK) 
 22, ‘Old Charm’, Old Mill Street 
Mellieha, MLH 1347 (Malta) 
Tel. +356 9985 3695, E-Mail oldcharm @  onvol.net 
 
563 
  
Acute Liver Impairment in a 
Young, Healthy Athlete: Hypoxic 
Hepatitis and Rhabdomyolysis 
following Heat Stroke 
Neville Azzopardia    Stephania Chetcutib    Jessica Santb    
James Pococka 
aGastroenterology Department, Mater Dei Hospital, and bMater Dei Hospital, 
Msida, Malta 
 
 
Key Words 
Hypoxic hepatitis · Ischaemic hepatitis · N-acetyl cysteine · Rhabdomyolysis 
 
 
Abstract 
Any process that substantially diminishes arterial blood flow or arterial oxygen content 
to the liver can result in hypoxic (ischaemic) hepatitis. 90% of hypoxic hepatitis occurs in 
unstable patients in intensive care units with haemodynamic failure secondary to heart 
failure, respiratory failure and toxic shock. The rate of in-hospital mortality in hypoxic 
hepatitis is very high with studies recording mortalities of 61.5%. It tends to be very 
uncommon in healthy, young patients with no underlying medical problems. We report 
here the case of a young healthy athlete who developed heat stroke associated with 
rhabdomyolysis and hypoxic hepatitis while he was running the final stages of a marathon. 
The patient required intensive care admission and inotropic support for a few hours after he 
was admitted with heat stroke. He underwent a rapid recovery after he was resuscitated 
with fluids. N-acetyl cysteine was also given during the acute stage of the hepatitis. This case 
highlights an uncommon case of hypoxic hepatitis in a young, healthy patient secondary to 
hypotension and heat stroke. Inotropic support might have precipitated the hypoxic 
hepatitis in this young patient. 
 
Introduction 
The liver receives nearly 30% of the total cardiac output with 70% of the total 
hepatic blood flow passing through the portal venous system and 30% passing through 
the hepatic arterial system. More than half of the oxygen supply to the liver is delivered 
by hepatic arterial blood. Any process that substantially reduces arterial blood flow or 
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arterial oxygen content to the liver can result in hypoxic hepatitis. Hypoxic hepatitis 
tends to be commoner in patients with systemic hypotension and other concomitant 
conditions which decrease the systemic or the hepatic circulation [1], and it occurs 
mostly in intensive care unit patients who are haemodynamically unstable.  
90% of cases occur secondary to heart failure, respiratory failure and toxic shock [2]. 
The most common cardiac disorders responsible for ischaemic hepatitis are acute 
myocardial infarction and arrhythmias. Valvular heart disease, cardiomyopathy and 
pericardial tamponade also can result in arterial hypotension complicated by ischaemic 
hepatitis. The rate of in-hospital mortality in hypoxic hepatitis is very high with studies 
reporting mortalities of 61.5%. Mortality tends to be higher in patients with septic 
shock (83.3%) and cardiac arrest (77.7%) [3]. Cases of hypoxic hepatitis were also 
reported in relation to specific conditions such as obstructive sleep apnoea [4], 
profound anaemia [5], complicated aortic aneurysms, acute lower limb ischaemia [6], 
hereditary haemorrhagic telangiectasia [7] and grand mal seizures [8]. However, 
hypoxic hepatitis rarely occurs in young healthy patients. Diminished portal venous 
blood flow increases the susceptibility to hypoxic hepatitis during episodes of arterial 
hypotension or hypoxia. Furthermore, diminished hepatic venous outflow (i.e. 
secondary to congestive heart failure, Budd-Chiari syndrome) and biliary obstruction 
also increase an individual’s risk for ischaemic hepatitis with hypotension or hypoxia 
[1]. 
Hypoxic hepatitis was previously known as ‘ischaemic hepatitis’ or ‘shock liver’. 
Liver ischaemia was until recently considered to be the only haemodynamic 
mechanism responsible for hypoxic hepatitis, and it was believed that a shock state was 
required. However, other haemodynamic mechanisms of hypoxia, such as passive 
congestion of the liver, arterial hypoxaemia and dysoxia, have been shown to be 
important mechanisms in inducing hepatocyte damage with a shock state being 
observed in only 50% of cases of hypoxic hepatitis. Accordingly, ‘ischaemic hepatitis’ 
and ‘shock liver’ are misnomers and the term ‘hypoxic hepatitis’ better describes this 
condition [2]. 
The diagnosis should be suspected in patients who have evidence of past or present 
cardiac disease, in the presence of electrocardiographic abnormalities or radiographic 
pulmonary abnormalities (found in about half of all patients with acute hypoxic 
hepatitis) and in patients with marked increases in transaminase activity together with 
a degree of initial renal impairment [9]. The outcome of hypoxic hepatitis is influenced 
by the severity of liver impairment and the aetiology and severity of the underlying 
conditions. Peak aspartate transaminase, lactate dehydrogenase, INR and lactate levels 
are higher in intensive care unit patients with fatal hypoxic hepatitis. The duration of 
hypoxia also appears to increase mortality [10]. 
Management involves treatment of the underlying conditions, with plenty of fluids in 
patients with hypotension and septic shock, maintaining adequate oxygenation in 
patients with underlying respiratory conditions and prompt management of cardiac 
disorders in order to restore haemodynamic stability. 
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Case Report 
We report here the case of a young healthy athlete who developed heat stroke associated with 
rhabdomyolysis and ischaemic hepatitis while he was running the final stages of a marathon. The 
athlete was a 25-year-old Hungarian gentleman who had been training for the Malta Marathon (held 
over 42.2 km) for several months. He was fit, having had regular medical check-ups during his 
training and before the marathon. The patient was feeling very well during the race, so much that he 
was improving on his usual time and towards the end of the race (41st km) decided to sprint the last 
few metres towards the finish line. He was noticed to collapse a few hundred metres from the finish 
and his next recollection was waking up in the intensive care unit at our centre. Upon his collapse, the 
paramedics found him to be severely hypotensive with unrecordable blood pressure. A peripheral line 
was inserted and he was started on intravenous fluids. He was rushed to accident and emergency 
where he was found to be confused, with a Glasgow Coma Score of 10. He had a temperature of 
105.4°F on admission and he was sweaty, tachycardic (heart rate of 160 bpm) and had a systolic 
blood pressure of 90 mm Hg. Preliminary investigations are shown in table 1. 
He was taken to the intensive care unit where he was resuscitated with plenty of fluids. His 
blood pressure remained very low, requiring inotropic support with ephedrine for 6 h. A CT scan of 
his brain was normal. He was also started on intravenous co-amoxiclav. Repeat blood investigations 
the day after admission revealed an elevated creatinine phosphokinase (CPK) level (178,850 U/l), 
suggesting underlying rhabdomyolysis. It was also noticed that the serum alanine aminotransferase 
(ALT) had started rising with a level of 143 U/l on day one post admission. 
The patient improved clinically, was responsive within a few hours and was transferred from 
intensive care to a general medical ward the following day. However, his ALT peaked on the second 
day of admission (table 2). On examination, there were no signs of chronic liver disease, no flap, and 
he was not jaundiced. Liver screen was normal with negative viral screen, autoimmune screen and 
mildly raised ferritin levels (table 2). An ultrasound of his liver was also normal. All non-essential 
treatment (including the antibiotic) was stopped and intravenous N-acetyl cysteine (NAC) was started 
at a dose of 100 mg/kg 16-hourly. He was discharged home with an early outpatients follow-up once 
both CPK and ALT were improving progressively (fig. 1, fig. 2). 
Discussion 
Graveling and Frier [11] reported a similar case report of a young insulin-dependent 
diabetic patient who suffered an episode of nocturnal hypoglycaemia which provoked a 
tonic-clonic seizure the day before a marathon. Despite this he ran in the marathon the 
following day during which he collapsed with severe hypoglycaemia and a further 
associated seizure. He subsequently developed severe myalgia accompanied by a 
pronounced and persistent elevation of plasma CPK, indicating rhabdomyolysis, and 
deranged liver function, suggestive of hypoxic hepatitis. The authors concluded that the 
rhabdomyolysis and hypoxic hepatitis occurred as a result of prolonged physical 
exercise following severe hypoglycaemia. 
Studies have shown that up to 11% of intensive care unit patients develop hypoxic 
hepatitis. Regression analysis has demonstrated a strong mortality risk for admissions 
with hypoxic hepatitis requiring vasopressor therapy, unlike hypoxic hepatitis in the 
absence of vasopressor therapy which does not appear to be significantly associated 
with mortality [12]. While it is relatively unexpected that a healthy, young athlete 
should develop hypoxic hepatitis, the vasopressors used for a short period in intensive 
care might have precipitated the hypoxic damage to the liver in our patient. The 
relatively short period of vasopressor use might also explain this patient’s rapid 
recovery with rapid improvement in his ALT levels. 
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NAC has been shown to limit liver injury and improve prognosis in patients with 
acute liver failure secondary to paracetamol overdose. NAC limits liver injury by 
repleting hepatic glutathione and increasing oxygen delivery to peripheral tissues [13]. 
While little evidence exists on the benefits of NAC in hypoxic hepatitis, it has been 
tested as a treatment for acute liver failure not related to paracetamol overdose. A 
placebo-controlled trial on 173 patients with acute liver failure that was not due to 
paracetamol overdose showed that patients treated with NAC had more transplant-free 
survival and less orthotopic liver transplantation at 1 year when compared with those 
receiving placebo [14]. Patients with grade 1 or 2 encephalopathy receiving NAC also 
had better 1-year survival than those receiving placebo. For this reason, NAC may have 
an important therapeutic role in the management of acute hepatitis secondary to 
hypoxia. 
 
 
 
Table 1. Initial blood investigations on admission 
   
   
 Values on  
admission 
Normal range 
   
   
White blood cells 12.3 3.5–11 × 109/l 
Neutrophils 8.0 2.5–7.5 × 109/l 
Haemoglobin 17.8 13–18 g/dl 
Platelets 254 140–400 × 109/l 
Creatinine 228 62–106 μmol/l 
Urea 5.90 1.7–8.3 mmol/l 
Potassium 4.66 3.5–5.1 mmol/l 
Random glucose 4.08 3.9–9.0 mmol/l 
INR 1.12 0.88–1.1 
CPK 515 39–308 U/l 
ALP 110 40–129 U/l 
ALT 34 5–41 U/l 
GGT 29 8–61 U/l 
Bilirubin 7.4 1.72–17.1 μmol/l 
Lactate 1.8  
Drugs of abuse screen negative  
Urine myoglobin test negative  
   
   
 
 
 Case Rep Gastroenterol 2012;6:563–568 
DOI: 10.1159/000338838 
Published online: 
August 28, 2012 
© 2012 S. Karger AG, Basel 
ISSN 1662–0631 
www.karger.com/crg 
 
 
 
567 
Table 2. Patient’s liver function tests and hepatitis screen on day 2 
following admission 
  
  
 Values on day 2 
  
  
ALP 110 
ALT 2,912 
GGT 128 
Bilirubin 36 
Hepatitis B surface antigen negative 
Hepatitis B core IgM antibody negative 
Hepatitis A IgM antibody negative 
Hepatitis C antibody negative 
Ferritin 621 (28–365 ng/ml) 
Anti-smooth muscle antibody negative 
Anti-mitochondrial antibody negative 
Anti-nuclear antibody negative 
  
  
 
 
 
 
 
Fig. 1. Chart describing the trend in ALT from admission until week 3 after discharge. The ALT level 
peaked at 2,912 U/l on day 2 post admission and then improved progressively. NAC was started on 
day 2. 
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Fig. 2. Chart describing the trend in CPK from admission until week 3 after discharge. The CPK level 
peaked at 178,850 U/l on day 1 post admission and improved rapidly with rehydration. 
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